Does statin use affect amyloid beta deposition and brain metabolism?

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) and tau pathology.
• Contradictory findings exist on statin drug effects on Aβ deposition.

Purpose of the Study:

• To longitudinally investigate the therapeutic and preventive roles of statin drugs.
• To examine brain Aβ deposition and metabolism rates in AD, mild cognitive impairment (MCI), and healthy controls (HC).

Main Methods:

• Utilized data from 828 subjects (178 HC, 492 MCI, 158 AD) from the ADNI database.
• Analyzed baseline and longitudinal [18F] AV45 and FDG PET SUVR measures in statin users versus non-users.

Main Results:

• No significant baseline differences in Aβ deposition or metabolism between statin users and non-users across groups.
• Statin use showed a significant difference in Aβ deposition change over 4 years in HC subjects (p=0.011).
• Statin dosage and total exposure correlated with reduced Aβ deposition in HC subjects at 2 years.

Conclusions:

• Statins may slow Aβ deposition in cognitively healthy individuals, potentially preventing age-related buildup.
• Statins do not appear to slow Aβ deposition once cognitive impairment symptoms manifest.
• Overall, statin users may exhibit slower Aβ aggregation compared to non-users.